Lipoglycopeptide Antibacterial [EPC]: Side Effects & Safety Data for 4 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Lipoglycopeptide Antibacterial [EPC] includes 4 drugs with a combined 2,349 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
4
Drugs in Class
2,349
Combined Reports
All Lipoglycopeptide Antibacterial [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| DALBAVANCIN | DALBAVANCIN HYDROCHLORIDE | 1,107 | 54 | 288 | 4.9% |
| ORITAVANCIN | Orbactiv | 884 | 29 | 157 | 3.3% |
| ORITAVANCIN DIPHOSPHATE | Kimyrsa | 276 | 4 | 27 | 1.4% |
| TELAVANCIN | VIBATIV | 82 | 3 | 25 | 3.7% |
Common Side Effects in Lipoglycopeptide Antibacterial [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Off label use | 441 | 21 |
| Pruritus | 263 | 2 |
| Rash | 208 | 1 |
| Chills | 204 | 4 |
| Back pain | 187 | 4 |
| Dyspnoea | 169 | 4 |
| Urticaria | 156 | 2 |
| Infusion related reaction | 155 | 2 |
| Nausea | 151 | 5 |
| Erythema | 132 | 1 |